Recent Updates
Recently added Catalysts
IMRX

January 2026 – Targeted Oncology

Key Takeaway: The article primarily discusses the privacy and cookie policies of a website, emphasizing the importance of user experience and analytics. It outlines how cookies are utilized to enhance site functionality and track visitor engagement. There are no specific biopharma news updates or events mentioned.
Price reaction · baseline $5.22 (2026-01-26 close) · hit pre-market · 1 other IMRX headline(s) in the window, move may be shared
day 0 close
+0.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor

Full Press Release Details

• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: Jan 27, 2026